Sotera Health’s (SHC) “Outperform” Rating Reaffirmed at Royal Bank of Canada

Sotera Health (NASDAQ:SHC)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Royal Bank of Canada in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $17.00 price objective on the stock. Royal Bank of Canada’s target price would suggest a potential upside of 32.81% from the company’s previous close.

Several other equities research analysts also recently commented on the stock. Citigroup upped their price objective on shares of Sotera Health from $18.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Barclays raised their price objective on shares of Sotera Health from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, August 6th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $16.50.

Sotera Health Stock Performance

SHC stock traded down $0.41 during mid-day trading on Thursday, hitting $12.80. The company had a trading volume of 238,087 shares, compared to its average volume of 1,300,829. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88. The firm has a market cap of $3.63 billion, a PE ratio of 51.48 and a beta of 2.08. Sotera Health has a 12 month low of $10.71 and a 12 month high of $17.44. The stock’s fifty day moving average price is $15.77 and its two-hundred day moving average price is $13.94.

Sotera Health (NASDAQ:SHC) last announced its quarterly earnings data on Tuesday, November 5th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). The firm had revenue of $285.47 million for the quarter, compared to the consensus estimate of $278.64 million. Sotera Health had a net margin of 6.31% and a return on equity of 42.27%. Sotera Health’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same period last year, the company posted $0.18 earnings per share. On average, analysts forecast that Sotera Health will post 0.61 earnings per share for the current fiscal year.

Insider Activity at Sotera Health

In related news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the business’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $15.03, for a total transaction of $150,300,000.00. Following the transaction, the director now owns 49,215,301 shares in the company, valued at $739,705,974.03. The trade was a 16.89 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 55.12% of the stock is owned by company insiders.

Institutional Trading of Sotera Health

Several large investors have recently bought and sold shares of SHC. CWM LLC lifted its stake in shares of Sotera Health by 86.1% in the 2nd quarter. CWM LLC now owns 2,146 shares of the company’s stock valued at $25,000 after purchasing an additional 993 shares during the period. True Wealth Design LLC bought a new stake in shares of Sotera Health during the 3rd quarter valued at $32,000. GAMMA Investing LLC grew its position in shares of Sotera Health by 125.0% in the 3rd quarter. GAMMA Investing LLC now owns 2,988 shares of the company’s stock worth $50,000 after buying an additional 1,660 shares during the period. Point72 DIFC Ltd increased its stake in shares of Sotera Health by 556.6% in the 2nd quarter. Point72 DIFC Ltd now owns 6,540 shares of the company’s stock worth $78,000 after acquiring an additional 5,544 shares in the last quarter. Finally, Capital Performance Advisors LLP purchased a new position in Sotera Health during the 3rd quarter valued at about $91,000. 91.03% of the stock is owned by institutional investors.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.